These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37759290)

  • 1. Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials.
    Godoi A; Reis Marques I; Padrão EMH; Mahesh A; Hespanhol LC; Riceto Loyola Júnior JE; de Souza IAF; Moreira VCS; Silva CH; Miyawaki IA; Oommen C; Gomes C; Silva AC; Advani K; de Sa JR
    Diabetol Metab Syndr; 2023 Sep; 15(1):190. PubMed ID: 37759290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
    Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
    Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B: results from randomized controlled trials.
    De Ridder F; den Brinker M; De Block C
    Ther Adv Endocrinol Metab; 2019; 10():2042018819871903. PubMed ID: 31516690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous glucose monitoring systems for type 1 diabetes mellitus.
    Langendam M; Luijf YM; Hooft L; Devries JH; Mudde AH; Scholten RJ
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD008101. PubMed ID: 22258980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
    Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
    Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does fully closed-loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta-analysis of randomized controlled trials.
    Amer BE; Yaqout YE; Abozaid AM; Afifi E; Aboelkhier MM
    Diabet Med; 2024 Jan; 41(1):e15196. PubMed ID: 37567739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.
    Teo E; Hassan N; Tam W; Koh S
    Diabetologia; 2022 Apr; 65(4):604-619. PubMed ID: 35141761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.
    Choudhary P; Kolassa R; Keuthage W; Kroeger J; Thivolet C; Evans M; Ré R; de Portu S; Vorrink L; Shin J; Habteab A; Castañeda J; da Silva J; Cohen O;
    Lancet Diabetes Endocrinol; 2022 Oct; 10(10):720-731. PubMed ID: 36058207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.